4//SEC Filing
REED ELIZABETH E 4
Accession 0001415889-24-023095
CIK 0001438533other
Filed
Sep 8, 8:00 PM ET
Accepted
Sep 9, 9:20 PM ET
Size
7.1 KB
Accession
0001415889-24-023095
Insider Transaction Report
Form 4
REED ELIZABETH E
Chief Legal Officer and GC
Transactions
- Award
Common Stock
2024-09-05+6,750→ 83,020 total - Sale
Common Stock
2024-09-09$11.52/sh−4,387$50,538→ 78,633 total
Footnotes (2)
- [F1]On January 31, 2023, the reporting person was granted performance restricted stock units (PSUs) covering 6,750 shares of the Issuer's common stock, which vest upon the satisfaction of certain performance criteria. On September 5, 2024, the PSUs vested upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted full approval to FILSPARI (sparsentan) in IgA Nephropathy.
- [F2]This sale was made pursuant to a written plan adopted March 15, 2024 meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001283303
Filing Metadata
- Form type
- 4
- Filed
- Sep 8, 8:00 PM ET
- Accepted
- Sep 9, 9:20 PM ET
- Size
- 7.1 KB